Precigen, Inc.

XNASHealth care

Last traded price · USD

$4.97

−1.68%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 15:51 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $5.06
Volume: 2,352
Day's high: —
Day's low: —

In brief

Precigen, Inc. is a health care company listed on Nasdaq, valued at about $1.78B.
Its shares closed at $5.06 on 4 Nov 2026, up 30.3% over the past year.
From India you can buy PGEN in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Precigen, Inc. (PGEN) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole PGEN share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade PGEN options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Ahead of SPY, in line with its sector fund XLV over 1 year
1 month: −33.0% (SPY −1.6%, XLV +13.5%). 3 months: −26.6% (SPY −0.4%, XLV +15.5%). 1 year: +30.3% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: PGEN, SPY and XLV · as of 4 Nov 2026
Below its 50- and 200-day averages
The 4 Nov 2026 close of $5.06 was 28.7% below its 50-day average ($7.09) and 4.3% below its 200-day average ($5.28). It has closed below the 200-day for 3 sessions, since 2 Nov 2026. The 50-day average crossed above the 200-day on 18 May 2026, 118 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
10.2 days to cover short interest
46.4M shares were sold short at the 15 Oct 2026 settlement, 13.0% of the 356.5M shares outstanding; covering them would take 10.2 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
34% of the way up its 52-week range
Closed at $5.06 on 4 Nov 2026: 43.7% below the 52-week high of $8.98 (30 Sep 2026) and 66.3% above the low of $3.04 (25 Mar 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
Volume 1.8× its 30-session average on 4 Nov 2026
4 Nov 2026 volume of 10.5M shares was 1.8× the average of the 30 sessions before it (5.8M), as the price fell 3.7%. SPY traded 1.5× its own average that session.
Daily volume against a 30-session baseline · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−33.0%

6 months+14.9%

1 year+30.3%

5 years−3.9%

Newswire

About

Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.

Website

Notable moves

November 2, 2026
−25.94%
August 15, 2025
+58.92%
December 30, 2024
+28.47%

Newswire

About

Website

Notable moves

November 2, 2026
−25.94%
August 15, 2025
+58.92%
December 30, 2024
+28.47%

Precigen, Inc.

XNASHealth care

Last traded price · USD

$4.97

−1.68%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 15:51 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $5.06
Volume: 2,352
Day's high: —
Day's low: —

In brief

Precigen, Inc. is a health care company listed on Nasdaq, valued at about $1.78B.
Its shares closed at $5.06 on 4 Nov 2026, up 30.3% over the past year.
From India you can buy PGEN in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Precigen, Inc. (PGEN) shares from India?

Do I need the price of a whole PGEN share to invest?

How much can I invest in US stocks in a year?

Can I trade PGEN options or futures?

Insights

Quotes run fifteen minutes behind.

Ahead of SPY, in line with its sector fund XLV over 1 year
1 month: −33.0% (SPY −1.6%, XLV +13.5%). 3 months: −26.6% (SPY −0.4%, XLV +15.5%). 1 year: +30.3% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: PGEN, SPY and XLV · as of 4 Nov 2026
Below its 50- and 200-day averages
The 4 Nov 2026 close of $5.06 was 28.7% below its 50-day average ($7.09) and 4.3% below its 200-day average ($5.28). It has closed below the 200-day for 3 sessions, since 2 Nov 2026. The 50-day average crossed above the 200-day on 18 May 2026, 118 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
10.2 days to cover short interest
46.4M shares were sold short at the 15 Oct 2026 settlement, 13.0% of the 356.5M shares outstanding; covering them would take 10.2 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
34% of the way up its 52-week range
Closed at $5.06 on 4 Nov 2026: 43.7% below the 52-week high of $8.98 (30 Sep 2026) and 66.3% above the low of $3.04 (25 Mar 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
Volume 1.8× its 30-session average on 4 Nov 2026
4 Nov 2026 volume of 10.5M shares was 1.8× the average of the 30 sessions before it (5.8M), as the price fell 3.7%. SPY traded 1.5× its own average that session.
Daily volume against a 30-session baseline · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−33.0%

6 months+14.9%

1 year+30.3%

5 years−3.9%

Newswire

About

Website

Notable moves

November 2, 2026
−25.94%
August 15, 2025
+58.92%
December 30, 2024
+28.47%

Newswire

About

Website

Notable moves

November 2, 2026
−25.94%
August 15, 2025
+58.92%
December 30, 2024
+28.47%

Precigen, Inc.

Precigen, Inc. in brief

Ahead of SPY, in line with its sector fund XLV over 1 year

Below its 50- and 200-day averages

10.2 days to cover short interest

34% of the way up its 52-week range

Volume 1.8× its 30-session average on 4 Nov 2026

Precigen, Inc.

Precigen, Inc. in brief

Ahead of SPY, in line with its sector fund XLV over 1 year

Below its 50- and 200-day averages

10.2 days to cover short interest

34% of the way up its 52-week range

Volume 1.8× its 30-session average on 4 Nov 2026